All in-house stories
In-house counsel
With resources under pressure, the Danish company’s IP leader explains how AI, smarter prioritisation and close business ties can help IP teams boost their impact. 7 October 2026
Pharma
Day one of the UK patent trial over blockbuster drug Jardiance put a lack of biological data, disputed evidence of testing and the limits of scientific prediction under the spotlight. 6 October 2026
In-house counsel
AI is helping legal and IP teams handle more work without adding headcount, but in-house counsel at LSPN Europe warn that knowing when not to rely on the technology is just as important as knowing how to use it. 2 October 2026
In-house counsel
With patent validity increasingly being fought over in both the UPC and EPO, Genevant Sciences’ Stephan Kutik talks to LSIPR about keeping parallel proceedings aligned and why teamwork matters. 1 October 2026
Regulation & Industry
LSPN Europe made its Basel debut, and two days of conversations showed just how much is changing for life sciences professionals—both in how they work and what they are being asked to do. Marisa Woutersen tallies up the talking points. 1 October 2026
Pharma
After a run of UK decisions going against major pharma patents on plausibility, Novartis bucked the trend with Entresto. The company’s lead counsel from Bristows explains why and what patentees can take from the ruling. 22 September 2026
In-house counsel
At an event attended by patent experts and judges from Europe, the US and China, delegates gathered in the innovation hub of Manchester, UK, to debate the theme of sustainability "in its broadest sense". Sarah Speight was there to hear ideas spanning the commercialisation of clean tech, to ensuring the patent profession’s resilience in a time of colossal change. 18 September 2026
Regulation & Industry
Pitching for business has always been a partner’s game. One in-house team decided junior lawyers needed a seat at the table, building a programme to close an “industry-wide gap” in vital experience. Marisa Woutersen spoke with organisers Regeneron and associates from A&O Shearman, Hoyng Rokh Monegier, and Bristows, who stepped up to ‘sell’ their firms. 14 September 2026
Regulation & Industry
Lawmakers support a bill that would place guardrails on lawyers’ use of generative AI for court filings, in a bid to clamp down on AI ‘hallucinations’ and inaccuracies. 4 September 2026
Regulation & Industry
Dozens of new and revised guidances could make it faster and less costly to bring generics to market, as the US ramps up pressure on drug prices. 27 August 2026